Existing atherosclerotic cardiovascular disease (ASCVD) risk calculators appear to be inadequate, noted researchers led by ...

PCSK9 inhibitor therapy is less likely to be utilized in Black, Hispanic, and low-income patients hospitalized with ...

Current cardiac screening tools used to prevent heart attacks fail to identify nearly half of the people who are actually at ...

Current cardiac screening tools used to prevent heart attacks fail to identify nearly half of the people who are actually at ...

Mount Sinai study shows that traditional risk scores and symptoms such as chest pain should not be solely relied upon to ...

Released in 2023, PREVENT is a tool estimating CVD, ASCVD, and heart failure risk over 10 or 30 years for adults as young as ...

Population-based age- and sex-specific percentiles for 30-year cardiovascular disease (CVD) risk have been developed based on ...

Scribe Therapeutics highlights data underpinning its comprehensive strategy targeting key lipid drivers of ASCVD at AHA Scientific Sessions 2025 ...

Trials of a new cholesterol-lowering pill have shown promising results for people with heterozygous familial ...

Current cardiac screening tools used to prevent heart attacks fail to identify nearly half of the people who are actually at risk of having one ...

Around half of study participants, all age 65 or younger, wouldn’t have been eligible for statins if they’d sought care 2 days earlier.

Statin therapy may attenuate the elevated MACE risk typically observed with tofacitinib vs TNF inhibitors among patients with RA and pre-existing ASCVD.